Read this company snapshot
Daily valuation snapshot
Valneva SE American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $5.78
- Market capitalization (USD)
- $501,529,863.05
- Price / earnings (TTM)
- Not reported
- Price / book
- 4.03
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research VALN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research VALN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing VALN with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $5.78 |
| Market capitalization (USD) | $501,529,863.05 |
| Price / earnings (TTM) | Not reported |
| Price / book | 4.03 |
No matching rows. Clear the filter to see all records.
Read VALN's valuation metrics
Company size
Valneva SE American Depositary Shares's recorded market capitalization is $501,529,863.05. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
VALN's recorded price-to-book ratio is 4.03. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Valneva SE American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about VALN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow VALN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.